Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorDieras, Veronique
dc.contributor.authorCortés Castan, Javier
dc.contributor.authorPatt, Debra
dc.contributor.authorWildiers, Hans
dc.contributor.authorO’Shaughnessy, Joyce
dc.contributor.authorZamora Adelantado, Esther
dc.contributor.authorRugo, Hope
dc.date.accessioned2021-10-19T10:12:12Z
dc.date.available2021-10-19T10:12:12Z
dc.date.issued2020-11
dc.identifier.citationRugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O’Shaughnessy J, et al. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1. Breast Cancer Res Treat. 2020 Nov;184:161-72.
dc.identifier.issn1573-7217
dc.identifier.urihttps://hdl.handle.net/11351/6406
dc.descriptionAbemaciclib; Càncer de mama metastàsic; Supervivència global
dc.description.sponsorshipThis study was funded by Eli Lilly and Company.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesBreast Cancer Research and Treatment;184
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Quimioteràpia
dc.subject.meshBreast Neoplasms
dc.subject.mesh/drug therapy
dc.titleReal-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s10549-020-05838-5
dc.subject.decsneoplasias de la mama
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://doi.org/10.1007/s10549-020-05838-5
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rugo HS] Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. [Dieras V] Centre Eugene Marquis UNICANCER, Rennes Cedex, France. [Cortes J] 3 IOB Institute of Oncology, Quironsalud Group, Madrid, Spain. 4 IOB Institute of Oncology, Quironsalud Group, Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Patt D] Texas Oncology, Austin, TX, USA. US Oncology, Dallas, TX, USA. [Wildiers H] Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium. [O'Shaughnessy J] Texas Oncology, US Oncology, Baylor University Medical Center, Dallas, TX, USA. [Zamora E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid32789591
dc.identifier.wos000559209800002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple